Fibrin-based biomatrix

• US 20050118144A1
• Filed: 06/23/2004
• Published: 06/02/2005
• Est. Priority Date: 05/02/2002
• Status: Active Grant

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Zhang, Jianyi
• Granted Patent: US 7,442,397 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61L 24/0005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 24/106 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/225 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3869 Epithelial tissues other than skin
• CPC Class Codes: A61L 27/3873 Muscle tissue, e.g. sphincter
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The invention involves methods and materials related to fibrin-based biomatrices.

Claims

1. A method for repairing damaged tissue in a mammal, said method comprising introducing, on or into a tissue in need of repair, a PEGylated fibrinogen solution comprising stem or progenitor cells under conditions wherein a fibrin biomatrix comprising said cells forms at or near the site of introduction.

2. The method of claim 1, wherein said tissue is skin.

3. The method of claim 1, wherein said tissue is cardiac tissue.

4. The method of claim 1, wherein said stem or progenitor cells are bone marrow cells.

5. The method of claim 4, wherein said bone marrow cells are autologous to said mammal.

6. The method of claim 1, wherein fibrinogen in said PEGylated fibrinogen solution is autologous to said mammal.

7. The method of claim 1, wherein said conditions comprise introducing a solution comprising a fibrinogen-converting agent to said PEGylated fibrinogen solution.

8. The method of claim 7, wherein said fibrinogen-converting agent is a serine protease.

9. The method of claim 8, wherein said serine protease is thrombin.

10. The method of claim 9, wherein said thrombin is autologous to said mammal.

11. The method of claim 7, wherein said fibrinogen-converting agent is added to said PEGylated fibrinogen solution before said introduction.

12. The method of claim 7, wherein said fibrinogen-converting agent is added to said PEGylated fibrinogen solution after said introduction.

13. A method of assisting tissue function in a mammal in need thereof comprising introducing, on or into a tissue, a PEGylated fibrinogen solution comprising stem or progenitor cells under conditions wherein a fibrin biomatrix comprising said cells forms at or near the site of introduction, and wherein said cells assist said tissue function of said mammal.

14. A method of delivering stem or progenitor cells to a tissue of a mammal comprising injecting, onto or in the vicinity of a surface of said tissue of said mammal, a PEGylated fibrinogen solution comprising said cells.

15. A method for inducing stem or progenitor cells to differentiate comprising:

a) providing said cells in a fibrinogen solution; and

b) introducing said PEGylated fibrinogen solution onto a tissue of a mammal under conditions wherein a fibrin biomatrix comprising said cells forms at or near the site of introduction and said cells differentiate.

16. An article of manufacture, comprising

a PEGylated fibrinogen solution;

a thrombin solution; and

instructions for forming a fibrin biomatrix.

17. The article of manufacture of claim 16, further comprising:

instructions for collecting stem or progenitor cells from a mammal.

18. The article of manufacture of claim 16, further comprising:

a therapeutic compound.

19. The article of manufacture of claim 18, wherein said therapeutic compound is a drug.